Enzyme-linked immunosorbent assay of phenolic glycolipid-I in patients with Hansen's disease

被引:0
作者
Hernando Moreno, Luis [1 ]
Alzate, Alberto [2 ]
机构
[1] Univ Valle, Fac Salud, Cali, Colombia
[2] Univ Santiago Cali, Cali, Colombia
来源
COLOMBIA MEDICA | 2010年 / 41卷 / 02期
关键词
ELISA; Hansen; Mycobacterium leprae; Phenolic glycolipid; Leprosy; MYCOBACTERIUM-LEPRAE; IGM ANTIBODIES; LEPROSY PATIENTS; SERA;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Hansen's disease or leprosy is a contagious-infection entity produced by the Hansen bacillus or Mycobacterium leprae. The phenolic glycolipid is a special trisaccharide found in the bacillus cell wall and proved to be specific and immunogenic species during M. leprae. Objective: To determine the presence of the Hansen bacillus enzyme-linked immunoassay (ELISA) method glycolipid phenolic I in a group of patients in Dermatology Consultation at the Valle del Cauca Health Services; these patients were classified as cures or under watch according to criteria established by the World Health Organization (WHO). Methodology: From the data base of the Dermatology Consultation at the Valle del Cauca Health Services, we studied 159 patients with Hansen's disease who were tested with the enzyme-linked immunoassay (ELISA) with the phenolic glycolipid I to cross reference information and observe if they were or were not positive to this test. A positive ELISA indicates the bacillus is still present in the patient. Results: As an important fact, we found that of 78 patients cured, when bearing in mind the monitoring period, 9 were positive for the ELISA. When this period was discarded, 81 sick individuals were classified as cured according to WHO criteria but the same 9 continued positive for ELISA. Conclusion: It may be concluded that in spite of meeting WHO criteria, these patients still show presence of the bacillus and the monitoring period is not required as a criterion to discharge a patient. We recommend adding to WHO criteria a negative ELISA, to obtain additional information that helps to certify that a patient is or is not cured.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 20 条
  • [1] ABE M, 1993, REV FRONT LEPROL, P299
  • [2] BAGSHAWE AF, 1990, INT J LEPROSY, V58, P25
  • [3] BATCH MA, 1986, INT J LEPROSY MYCOBA, V54, P256
  • [4] BRETT SJ, 1986, CLIN EXP IMMUNOL, V64, P476
  • [5] Leprosy
    Britton, WJ
    Lockwood, DNJ
    [J]. LANCET, 2004, 363 (9416) : 1209 - 1219
  • [6] CASAL M, 1996, MICROBIOLOGIA MED GE, P378
  • [7] CHO SN, 1991, INT J LEPROSY, V59, P25
  • [8] Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy
    Cho, SN
    Cellona, RV
    Villahermosa, LG
    Fajardo, TT
    Balagon, MVF
    Abalos, RM
    Tan, EV
    Walsh, GP
    Kim, JD
    Brennan, PJ
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2001, 8 (01) : 138 - 142
  • [9] GONZALEZ OCE, 2001, REV PANAN SALUD PUBL, V9, P97
  • [10] A NOVEL PHENOLIC GLYCOLIPID FROM MYCOBACTERIUM-LEPRAE POSSIBLY INVOLVED IN IMMUNOGENICITY AND PATHOGENICITY
    HUNTER, SW
    BRENNAN, PJ
    [J]. JOURNAL OF BACTERIOLOGY, 1981, 147 (03) : 728 - 735